TL;DR
Get everyday helpers delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Researchers combined six studies involving 2,684 older adults with no cognitive impairment and found that very high blood levels of p-tau217 were associated with an estimated 38% risk of cognitive impairment within five years and 78% within 10 years. The 10-year estimate rests on substantially less data, and researchers say current blood tests are not recommended for routine screening of people without symptoms.
A blood marker associated with Alzheimer’s disease was linked to the likelihood of future cognitive impairment in older adults who had no noticeable problems when they joined a large international study. Among participants with very high p-tau217 levels, researchers estimated a 38% chance of impairment within five years and a 78% chance within 10 years; they cautioned that the longer-term estimate is less certain because it draws on substantially less data.
The study, led by researchers at the Mass General Brigham Neuroscience Institute, pooled information from six observational studies and clinical trials in North America, Japan and Australia. It included 2,684 older adults who showed no signs of cognitive impairment at enrollment. Researchers measured blood levels of phosphorylated tau 217, or p-tau217, and used brain scans and annual assessments to track participants’ health over time.
About 478 participants developed cognitive impairment during follow-up. Participants entered studies as early as 2004, and the latest follow-up assessments took place in 2025. Higher p-tau217 levels were associated with greater likelihood of later cognitive problems. The reported percentages describe estimated risk among people with very high levels; they do not mean everyone with such a result will develop impairment.
The researchers said p-tau217 remained associated with future impairment after accounting for amyloid-beta plaques detected through PET imaging and genetic risk factors including APOE4. The findings were presented at the Alzheimer’s Association International Conference and published simultaneously in JAMA. They add evidence about risk prediction, but do not establish that a blood test can diagnose a person’s future with certainty.
What a Risk Estimate Could Change
The findings address a practical question: whether a blood test might offer information about future cognitive problems before symptoms appear. A blood test could be easier to access than brain imaging, and a risk estimate could eventually help clinicians identify people who might be eligible for prevention studies or treatments. The study does not show that testing itself prevents impairment or improves health outcomes.
For now, the researchers say the results do not support routine testing of people without symptoms. Preventive, disease-modifying treatments for otherwise healthy people identified as high risk have not been established, so a result may not change medical care. The distinction matters: a marker associated with future risk is not the same as a diagnosis, and the study’s percentages are group estimates, not a guarantee for any individual.
Products Worth Considering
LG UltraGear 32GS60QC-B 32-inch Curved QHD Gaming Monitor (180Hz, 1ms, 1000R, AMD FreeSync, HDR10)
LG UltraGear 32GX850A-B 32-inch 4K UHD Glossy OLED Gaming Monitor
Apple MacBook Air 13.6-inch with M5 Chip, 16GB Memory, 512GB SSD, Sky Blue
As an affiliate, we earn on qualifying purchases.
How Researchers Tracked Risk
Researchers measured p-tau217 in blood samples collected when participants entered the studies. Participants also had PET brain scans to establish baseline measures of brain health, followed by annual assessments of memory, thinking and other cognitive abilities. Combining six cohorts allowed the team to compare initial biomarker levels with outcomes across a longer span than a single study might provide.
A p-tau217 blood test recently received federal clearance, according to the source report, prompting interest in whether these tests can do more than detect Alzheimer’s-related biological changes. This study examined whether the marker could help estimate the chance of later cognitive impairment in people who were cognitively unimpaired at the outset. Its findings concern risk prediction; they do not mean a cleared test is recommended for screening healthy people.
“This is a critical step toward better understanding what p-tau217 can tell us about a person’s risk for cognitive impairment.”
— Rachel F. Buckley, lead author and cognitive neuroscientist at the Mass General Brigham Neuroscience Institute
Limits of the Long-Term Estimates
The 78% estimate at 10 years is less certain than the five-year result because substantially fewer observations were available for the longer follow-up period. The study also brought together participants from selected research cohorts, who may not represent the wider population. The source report does not provide enough detail to determine how well the estimates would apply across different demographic groups or in routine clinical settings.
The results show an association between p-tau217 and later cognitive impairment; they do not establish that every person with a high result will develop symptoms, or specify exactly when that might happen. The source material also does not establish how much an individual’s risk estimate would change clinical decisions. Researchers say blood tests are not currently recommended for routine Alzheimer’s risk screening in people without symptoms.
Treatment Trials May Shape Use
The next major question is whether ongoing trials of disease-modifying therapies show benefits for people identified as being at elevated risk. Sperling said that if such treatments prove beneficial, blood tests could eventually help identify people who might benefit. Until then, the study supports further research into prediction, not a change to screening advice for asymptomatic people.
Further work will also need to test how risk estimates perform in broader and more diverse populations and how they should be interpreted alongside other health information. The study’s authors advise that current medical guidance for people without symptoms remains the same regardless of a blood test result: regular exercise, a healthy diet, sleep and overall wellness.
Key Questions
What is p-tau217?
p-tau217 is a blood biomarker associated with Alzheimer’s disease. In this study, researchers examined whether its level could help estimate the likelihood of future cognitive impairment in older adults who had no impairment when they enrolled.
Does a high p-tau217 result mean someone will develop Alzheimer’s?
No. The study found an association between very high levels and later cognitive impairment, but its risk percentages are estimates for a group, not a certainty for an individual. A biomarker result is not the same as a diagnosis or a guarantee that symptoms will develop.
How strong were the five- and 10-year estimates?
For participants with very high p-tau217 levels, researchers estimated a 38% chance within five years and a 78% chance within 10 years. The 10-year estimate is less certain because it was based on substantially fewer observations.
Should people without symptoms get tested?
The researchers do not recommend currently available blood tests for routine risk screening in people without symptoms. They say disease-modifying treatments for otherwise healthy people identified as high risk have not been established.
What could change the role of these tests?
Results from ongoing trials of disease-modifying therapies could affect whether blood tests have a role in identifying people who may benefit from prevention. The researchers also say testing needs further evaluation in broader populations.
Source: sciencedaily.com
